Información de Longeveron Inc, dividendo de Longeveron Inc, actividades de los accionistas y más

Más Datos de Longeveron Inc Compañía

Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Información de Longeveron Inc



Símbolo de cotizaciónLGVN

Nombre de la empresaLongeveron Inc

Fecha de salida a bolsaFeb 12, 2021

Director ejecutivoMr. Wa'el Hashad

Número de empleados25

Tipo de seguridadOrdinary Share

Fin del año fiscalFeb 12

Dirección1951 NW 7th Ave

CiudadMIAMI

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal33136

Teléfono13053027158

Sitio Webhttps://www.longeveron.com/

Símbolo de cotizaciónLGVN

Fecha de salida a bolsaFeb 12, 2021

Director ejecutivoMr. Wa'el Hashad

Ejecutivos de Longeveron Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Joshua M. Hare, M.D.

Executive Chairman of the Board, Co-Founder, Chief Science Officer

253.07K

-2.03%

Ms. Lisa Locklear

Chief Financial Officer, Treasurer

152.42K

-7.23%

Dr. Nataliya Agafonova, M.D.

Chief Medical Officer

140.15K

-7.82%

Mr. Devin Blass

Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls

102.54K

-6.91%

Mr. Khoso Baluch

Independent Director

41.36K

+39.76%

Ms. Ursula Ungaro, J.D.

Independent Director

35.55K

+91.64%

Mr. Richard N. Kender

Independent Director

22.33K

+318.71%

Mr. Roger Joseph Hajjar

Independent Director

21.00K

+425.00%

Ms. Neha Motwani

Independent Director

21.00K

+425.00%

Dr. George Paletta

Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Joshua M. Hare, M.D.

Executive Chairman of the Board, Co-Founder, Chief Science Officer

253.07K

-2.03%

Ms. Lisa Locklear

Chief Financial Officer, Treasurer

152.42K

-7.23%

Dr. Nataliya Agafonova, M.D.

Chief Medical Officer

140.15K

-7.82%

Mr. Devin Blass

Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls

102.54K

-6.91%

Mr. Khoso Baluch

Independent Director

41.36K

+39.76%

Ms. Ursula Ungaro, J.D.

Independent Director

35.55K

+91.64%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

Por negocioUSD

Nombre

Ganancia

Proporción

Clinical trial revenue

298.00K

94.30%

Contract manufacturing

12.00K

3.80%

Contract manufacturing lease revenue

6.00K

1.90%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Clinical trial revenue

298.00K

94.30%

Contract manufacturing

12.00K

3.80%

Contract manufacturing lease revenue

6.00K

1.90%

Estadísticas de accionistas

Actualizado: mié., 29 de oct

Accionistas

Tipos de accionistas

Accionistas

Proporción

Lincoln Alternative Strategies LLC

6.01%

Armistice Capital LLC

3.45%

Lehr (Paul T)

1.66%

Hashad (Mohamed Wa'el Ahmed)

1.59%

Hare (Joshua M)

1.29%

Otro

85.99%

Accionistas

Proporción

Lincoln Alternative Strategies LLC

6.01%

Armistice Capital LLC

3.45%

Lehr (Paul T)

1.66%

Hashad (Mohamed Wa'el Ahmed)

1.59%

Hare (Joshua M)

1.29%

Otro

85.99%

Tipos de accionistas

Accionistas

Proporción

Individual Investor

9.26%

Corporation

6.01%

Hedge Fund

3.96%

Investment Advisor

1.66%

Investment Advisor/Hedge Fund

1.09%

Venture Capital

0.25%

Bank and Trust

0.02%

Otro

77.75%

Participación institucional



Actualizado: dom., 5 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

58

1.37M

6.98%

+569.67K

2025Q2

73

2.18M

16.11%

+296.38K

2025Q1

73

2.14M

15.82%

-119.71K

2024Q4

73

2.53M

18.80%

+652.31K

2024Q3

67

2.33M

17.58%

+1.38M

2024Q2

67

924.88K

16.16%

+194.99K

2024Q1

64

168.05K

15.95%

-258.83K

2023Q4

68

363.47K

37.19%

+110.22K

2023Q3

73

198.13K

31.46%

-72.89K

2023Q2

70

193.49K

31.19%

-39.22K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Lincoln Alternative Strategies LLC

1.18M

6.01%

+1.18M

--

Aug 08, 2025

Armistice Capital LLC

676.23K

3.45%

+676.23K

--

Sep 30, 2024

Lehr (Paul T)

330.30K

2.42%

+100.44K

+43.69%

Jul 15, 2025

Hashad (Mohamed Wa'el Ahmed)

310.90K

1.59%

+166.85K

+115.83%

Jul 15, 2025

Hare (Joshua M)

253.07K

1.29%

-5.25K

-2.03%

May 16, 2025

Soffer (Rock J)

179.52K

0.92%

+17.00K

+10.46%

Jul 15, 2025

Locklear (Lisa)

164.30K

0.85%

+11.77K

+7.71%

Aug 11, 2025

The Vanguard Group, Inc.

144.27K

0.74%

--

Jun 30, 2025

Geode Capital Management, L.L.C.

141.50K

0.72%

+770.00

+0.55%

Jun 30, 2025

Agafonova (Nataliya)

152.03K

1.12%

+94.57K

+164.57%

Jul 15, 2025

ETFs relacionados



Actualizado: dom., 2 de nov

Nombre

Proporción

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proporción0%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Fecha

Tipo

Relación

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1